Review
Immunology
Qian Chen, Jie Wang, Mengmeng Xiang, Yilun Wang, Zhixiong Zhang, Jun Liang, Jinhua Xu
Summary: This review summarizes the potential links between ferroptosis and systemic lupus erythematosus (SLE), elucidates the role of ferroptosis in SLE pathogenesis, and proposes a new therapeutic strategy for SLE.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Gabriela Guzman-Martinez, Concepcion Maranon
Summary: Patients with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease (CVD), which is becoming one of the most relevant complications and a significant factor causing morbidity and mortality in SLE. Immune constituents, including specific circulating cell populations, autoantibodies, and inflammatory mediators, play a role in the pathogenesis of atherosclerosis and endothelial damage in SLE patients. This review summarizes the presentation of CVD in SLE, the role of autoimmune responses in inducing atherogenesis, endothelial impairment, and cardiac disease, and discusses the utility of immune mediators as early CVD biomarkers and targets for clinical intervention in SLE patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Zhenrui Shi, Yu-ping Zhang, Dan Hong, Xiaonan Qiu, Lin Zheng, Lijuan Bian, Fengqiu Hu, Liuyu Chen, Hui Xiong, Qiongqiong Yang, Shanping Jiang, Guozhen Tan, Liangchun Wang
Summary: Vascular inflammation can occur in various organs and tissues in patients with systematic lupus erythematosus (SLE), with the skin being the most common site. Anti-galectin-3 (Gal3) antibodies are identified as an important mediator of lupus cutaneous vasculopathy. The dys-regulation of vascular endothelial cells by anti-Gal3 antibodies leads to increased production of IL-10, which is dependent on NLRP3 inflammasome. Injection of anti-Gal3 antibodies in mice induces local inflammation with immune cell infiltration, which can be inhibited by blocking IL-10. Induction of anti-Gal3 antibodies in circulation not only causes skin histopathologic changes but also systemic autoimmune phenotypes and kidney damage. IL-10 overexpression is primarily associated with skin lesions in mice. The serum levels of IL-10 are comparable between SLE patients and healthy donors, but there is higher IL-10 expression in the local area of lupus skin lesions. These results suggest the important role of IL-10 in mediating anti-Gal3 antibody-induced skin vascular inflammation and the potential use of IL-10 blocking therapies in treating lupus cutaneous damage.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Julie Sarrand, Muhammad Soyfoo
Summary: IL-33 is a newly discovered cytokine that acts as an alarmin to alert the innate immune system following cell death or necrosis. It has been found to be significantly upregulated in patients with SLE and lupus nephritis, suggesting its involvement in the pathology of SLE.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Medicine, General & Internal
Johan Frostegard
Summary: The prognosis in systemic lupus erythematosus (SLE) has improved, but cardiovascular disease (CVD) still remains a significant clinical problem. Atherosclerosis and antiphospholipid antibody syndrome are the main underlying causes of CVD in SLE. Inflammation and low levels of anti-phosphorylcholine also contribute to the increased risk of CVD in SLE. Close monitoring and treatment of both traditional and non-traditional risk factors are important.
JOURNAL OF INTERNAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Holly Ryan, Laurence Morel, Erika Moore
Summary: Vascular inflammation caused by overly activated immune cells is a significant factor contributing to morbidity and mortality in systemic lupus erythematosus (SLE). There are several mouse models currently used to study the pathogenesis of SLE, each with different mechanisms. The diversity of these models allows for the investigation of different aspects of the disease. To better understand the mechanisms of vascular inflammation in SLE and assist future researchers in selecting appropriate mouse models to study cardiovascular complications, it is suggested to directly compare vascular inflammation among different mouse models of SLE. Additionally, the use of in vitro vascular assays is proposed to further investigate prevalent vascular inflammation processes in different mouse models of SLE.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Brittany N. Weber, Emma Stevens, Leanne Barrett, Camden Bay, Corine Sinnette, Jenifer M. Brown, Sanjay Divakaran, Courtney Bibbo, Jon Hainer, Sharmila Dorbala, Ron Blankstein, Katherine Liao, Elena Massarotti, Karen Costenbader, Marcelo F. Di Carli
Summary: This study found that patients with systemic lupus erythematosus (SLE) without obstructive coronary artery disease have a high prevalence of coronary vasomotor abnormalities. This phenomenon is not solely explained by common cardiovascular factors or atherosclerotic burden.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Review
Immunology
Neelakshi R. Jog, Judith A. James
Summary: Infections or infectious reactivation can trigger systemic lupus erythematosus (SLE), and Epstein-Barr virus (EBV) is associated with various autoimmune diseases, including SLE. Recent advances suggest that EBV may play a role in immune dysregulation and its relationship to SLE disease progression.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Nutrition & Dietetics
Tanja Knopp, Tabea Bieler, Rebecca Jung, Julia Ringen, Michael Molitor, Annika Jurda, Thomas Muenzel, Ari Waisman, Philip Wenzel, Susanne Helena Karbach, Johannes Wild
Summary: Different dietary protein levels had minimal impact on the development and severity of IMQ-induced psoriasis, but aggravated the systemic pro-inflammatory phenotype. High protein diet slightly aggravated skin inflammation, while both high and low protein diets increased circulating neutrophils and reactive oxygen species after IMQ-treatment.
Article
Biochemistry & Molecular Biology
Paolo Fagone, Eliana Piombino, Katia Mangano, Rocco De Pasquale, Ferdinando Nicoletti, Rosario Caltabiano
Summary: This study found a negative correlation between HMOX1 levels and the inflammatory status, as well as the infiltration of M1 macrophages and activated mastocytes in DLE lesions. These findings suggest that HMOX1 plays a crucial role in the regulation of inflammation in DLE and could be a potential therapeutic target and biomarker for DLE.
Review
Biochemistry & Molecular Biology
Patricia Richter, Anca Cardoneanu, Ciprian Rezus, Alexandra Maria Burlui, Elena Rezus
Summary: Cardiovascular diseases are a leading cause of high mortality in SLE patients, and traditional risk factors are insufficient in predicting their risk. Inflammation has been found to play a crucial role in the development of atherosclerosis in SLE, highlighting the need for new biomarkers to assess subclinical CVD risk.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Julia Mercader-Salvans, Maria Garcia-Gonzalez, Juan C. Quevedo-Abeledo, Adrian Quevedo-Rodriguez, Alejandro Romo-Cordero, Soledad Ojeda-Bruno, Fuensanta Gomez-Bernal, Raquel Lopez-Mejias, Candelaria Martin-Gonzalez, Miguel A. Gonzalez-Gay, Ivan Ferraz-Amaro
Summary: Ratios derived from complete blood count can be used as inflammatory biomarkers in systemic lupus erythematosus (SLE) patients. Despite lower cell counts, NLR, MLR, and PLR are higher in SLE patients. However, the relationship between these scores and disease characteristics is limited, with the complement system being the most consistent.
Review
Peripheral Vascular Disease
Rachel Tobin, Nidhi Patel, Kardie Tobb, Brittany Weber, Puja K. Mehta, Ijeoma Isiadinso
Summary: SLE patients have an increased risk of cardiovascular disease (CVD) despite most patients being young females not traditionally considered at high risk. The increased risk is multifactorial, involving proatherogenic lipid profiles, immune dysregulation and inflammation, lupus treatment side effects, and microvascular dysfunction. Conventional CV risk models often fail to identify SLE patients at high risk for atherosclerosis. Non-invasive imaging is useful for identifying subclinical CVD and evaluating symptomatic patients. Prompt detection and treatment of atherosclerotic CVD in SLE patients is crucial.
CURRENT ATHEROSCLEROSIS REPORTS
(2023)
Review
Cell Biology
Allison B. Reiss, Benna Jacob, Saba Ahmed, Steven E. Carsons, Joshua DeLeon
Summary: Despite advancements in treating lupus, there is still a lack of innovative therapeutics specifically targeting the progression of atherosclerosis within the SLE population. Development of promising modalities for diagnosis of subclinical atherosclerosis and detection of high CVD risk patients has been achieved, but research addressing prevention and treatment of CVD in SLE needs to be prioritized due to its significant impact on morbidity and mortality.
Article
Immunology
Mengmeng Xiang, Yilun Wang, Zhanyan Gao, Jie Wang, Qian Chen, Zhan Sun, Jun Liang, Jinhua Xu
Summary: This study used Mendelian randomization to assess the causal correlations between 41 inflammatory cytokines and systemic lupus erythematosus (SLE). The results suggested that CTACK and IL-17 may be associated with the risk of SLE, while several other inflammatory cytokines may be consequences of SLE development.
FRONTIERS IN IMMUNOLOGY
(2023)
